C. Ambrosini is an FIRC fellowship recipient and N. Vannini is supported by the Immunopathology PhD program.
AKT/NF-κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies
Version of Record online: 6 SEP 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 9, pages 2007–2011, 1 November 2007
How to Cite
Dell'Eva, R., Ambrosini, C., Vannini, N., Piaggio, G., Albini, A. and Ferrari, N. (2007), AKT/NF-κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer, 110: 2007–2011. doi: 10.1002/cncr.23017
- Issue online: 18 OCT 2007
- Version of Record online: 6 SEP 2007
- Manuscript Accepted: 8 AUG 2007
- Manuscript Revised: 22 MAY 2007
- Manuscript Received: 4 APR 2007
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute Progetto Finalizzato
- Compagnia di San Paolo
Leukemias are dependent on Akt/NF-κB activation and angiogenesis.
The antiangiogenic Akt/NF-κB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.
Inhibition of cell proliferation is associated with induction of apoptosis and reduced VEGF secretion. Decreased cell invasion, metalloprotease production, and adhesion to endothelial cells observed in the presence of XN could prevent in vivo life-threatening complications of leukostasis and tissue infiltration.
As endothelial cells and hematopoietic cells are mutually correlated in their development and growth, targeting both tumor cells and endothelial cells with agents possessing cytotoxic and antiangiogenic activities may lead to synergistic antitumor effects interrupting a reciprocal stimulatory loop between leukemia and endothelial cells. Cancer 2007. © 2007 American Cancer Society.